Correction to: Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial (Neuropsychopharmacology, (2022), 47, 8, (1574-1581), 10.1038/s41386-022-01266-9)

Chadi G. Abdallah, John D. Roache, Ralitza Gueorguieva, Lynnette A. Averill, Stacey Young-McCaughan, Paulo R. Shiroma, Prerana Purohit, Antoinette Brundige, William Murff, Kyung Heup Ahn, Mohamed A. Sherif, Eric J. Baltutis, Mohini Ranganathan, Deepak D’Souza, Brenda Martini, Steven M. Southwick, Ismene L. Petrakis, Rebecca R. Burson, Kevin B. Guthmiller, Argelio L. López-RocaKarl A. Lautenschlager, John P. McCallin, Matthew B. Hoch, Alexandar Timchenko, Sergio E. Souza, Charles E. Bryant, Jim Mintz, Brett T. Litz, Douglas E Williamson, Terence M. Keane, Alan L Peterson, John H. Krystal

Research output: Contribution to journalComment/debatepeer-review

Fingerprint

Dive into the research topics of 'Correction to: Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial (Neuropsychopharmacology, (2022), 47, 8, (1574-1581), 10.1038/s41386-022-01266-9)'. Together they form a unique fingerprint.

Medicine and Dentistry

Nursing and Health Professions

Pharmacology, Toxicology and Pharmaceutical Science

Neuroscience

Immunology and Microbiology